A Double-Blind, Randomized, Three-arm, Active-Controlled, Parallel-Group, Phase 1 Study Evaluating Pharmacokinetic Similarity of Three Formulations of Pembrolizumab (CT-P51, EU-approved Keytruda, and US-licensed Keytruda) as Adjuvant Therapy in Patients with Completely Resected Stage IIB, IIC, and III Melanoma
Phase 1 – testing safety in a small group of people
Conditions:
Completely Resected Stage IIB
IIC
and III Melanoma
Sponsor: Celltrion Inc.
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 83 participants
БГ